Regional control after precision lymph node dissection for clinically evident melanoma metastasis Journal Article


Authors: Lynch, K. T.; Hu, Y.; Farrow, N. E.; Song, Y.; Meneveau, M. O.; Kwak, M.; Lowe, M. C.; Bartlett, E. K.; Beasley, G. M.; Karakousis, G. C.; Slingluff, C. L. Jr
Article Title: Regional control after precision lymph node dissection for clinically evident melanoma metastasis
Abstract: Introduction: Completion lymph node dissection (CLND) for microscopic lymph node metastases has been replaced by observation; however, CLND is standard for clinically detectable nodal metastases (cLN). CLND has high morbidity, which may be reduced by excision of only the cLN (precision lymph node dissection [PLND]). We hypothesized that same-basin recurrence risk would be low after PLND. Methods: Retrospective review at four tertiary care hospitals identified patients who underwent PLND. The primary outcome was 3-year cumulative incidence of isolated same-basin recurrence. Results: Twenty-one patients underwent PLND for cLN without synchronous distant metastases. Reasons for forgoing CLND included patient preference (n = 11), comorbidities (n = 5), imaging indeterminate for distant metastases (n = 2), partial response to checkpoint blockade (n = 1), or not reported (n = 2). A median of 2 nodes (range: 1–6) were resected at PLND, and 68% contained melanoma. Recurrence was observed in 33% overall. Only 1 patient (5%) developed an isolated same-basin recurrence. Cumulative incidences at 3 years were 5.0%, 17.3%, and 49.7% for isolated same-basin recurrence, any same-basin recurrence, and any recurrence, respectively. Complications from PLND were reported in 1 patient (5%). Conclusions: These pilot data suggest that PLND may provide adequate regional disease control with less morbidity than CLND. These data justify prospective evaluation of PLND in select patients. © 2022 Wiley Periodicals LLC.
Keywords: adult; clinical article; human tissue; aged; cancer surgery; temozolomide; positron emission tomography; recurrence risk; follow up; lymph node dissection; ipilimumab; melanoma; computer assisted tomography; retrospective study; distant metastasis; immunotherapy; multicenter study; adjuvant chemotherapy; needle biopsy; comorbidity; recurrent disease; inguinal lymph node; local metastasis; fatality; cumulative incidence; metastatic melanoma; patient preference; nodal metastases; dabrafenib; trametinib; nivolumab; human; male; female; article; pembrolizumab; tertiary care center; x-ray computed tomography; precision nodal dissection
Journal Title: Journal of Surgical Oncology
Volume: 127
Issue: 1
ISSN: 0022-4790
Publisher: Wiley Blackwell  
Date Published: 2023-01-01
Start Page: 140
End Page: 147
Language: English
DOI: 10.1002/jso.27100
PUBMED: 36115028
PROVIDER: scopus
PMCID: PMC11830148
DOI/URL:
Notes: Article -- Export Date: 3 January 2023 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors